Presented by

International Association for the Study of Lung Cancer

Jointly Sponsored by

  

Penn State College of Medicine and Rockpointe

Program Description

Non–small-cell lung cancer (NSCLC) can no longer be considered a homogeneous disease. Histologic and molecular features of NSCLC predict response to targeted agents, as well as certain chemotherapies; therefore, therapy must be individualized according to these criteria to maximize patient outcomes. Gender should also play a role in the individualization of care, as lung cancer biology, natural history, and treatment outcomes vary between men and women. The rapid evolution of the treatment paradigm for NSCLC has generated practice gaps among clinicians surrounding the current best practices that can improve outcomes for NSCLC patients.

Target Audience

This program is intended for medical oncologists, radiation oncologists, surgical oncologists, thoracic surgeons, pulmonologists, NPs, PAs, nurses, fellows and other healthcare professionals who are involved in the care of patients with NSCLC.

Educational Objectives

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

• Discuss the impact of gender on epidemiology of NSCLC
• Discuss the impact of gender on treatment outcomes in NSCLC
• Adequately assess molecular biomarkers and histology reports in order to individualize therapies

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Penn State College of Medicine and Rockpointe. Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category I credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit, the post-test, or evaluation, please call Penn State Continuing Education at: 717-531-6483; or e-mail: ContinuingEd@hmc.psu.edu. Please reference activity code G5003-12-T.

Disclosure Statement

Penn State College of Medicine is committed to offering CME/CE programs that promote improvements or quality in health care and are developed free of the control of commercial interests. Reasonable efforts have been taken to ensure that our programs are balanced, independent, objective, scientific, and in compliance with regulatory requirements. Faculty and course directors have disclosed all relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Penn State also requires that faculty disclose any discussion of off-label or investigational uses included in their presentations. Disclosure of a relationship is not intended to suggest or condone bias in a presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute an opinion or endorsement or promotion by Penn State College of Medicine. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

Faculty Disclosures

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Joan H. Schiller, MD: Consultant/Advisor: Aggenix (serves on DSMC), AVEO, Amgen, Bayer, Biodesix, Bristol-Myers Squibb, Daiichi-Sankyo, Lilly, Merck, Oncothyreon, Onyx, Syndax, Telik, Genentech, Novartis, Pfizer (serves on DSMC), Synta, Geron, Celgene, ArQuile, Merrimak; Research Grant: Genentech, Novartis, Pfizer (serves on DSMC), Synta, Geron, Celgene, ArQuile, Merrimak

Edward Garon, MD: Consultant/Advisor:Boehringer-Ingelheim; Research Grant: Pfizer, Eli Lilly, Novartis, Genentech, AstraZeneca, GlaxoSmithKline

Heather Wakelee, MD: Clinical Trial: Genentech, Exelixis, Regeneron, AstraZeneca, Pfizer, Lilly, Bayer, Novartis

Planner and Manager Disclosures

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Rockpointe Corporation and Penn State College of Medicine staff involved with this activity have nothing to disclose.

Academic Reviewer for Penn State College of Medicine Chandra P. Belani, MD: Consultant/Advisor: Eli Lilly, Genentech

FDA Disclosure

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

Instructions for Participants and Obtaining CME Credit

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hour. To receive and print their certificates, participants must demonstrate mastery of the presented material via the post-test.

Provider Contact Information
For questions about CME credit for this activity, contact Penn State College of Medicine continuinged@hmc.psu.edu or 717-531-6483. Reference course # G4320-12-T

This activity is jointly sponsored by and .

Supported by an independent educational grant from Genentech BioOncology & Lilly USA, LLC.